PMID: 9178167May 1, 1997Paper

The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS/Riluzole Study Group III

Journal of Neurology
V MeiningerP Zeisser

Abstract

Recent controlled trials in outpatients with amyotrophic lateral sclerosis (ALS) indicate that riluzole prolongs tracheostomy-free survival. After 12 months' treatment, riluzole 50 mg, 100 mg and 200 mg daily reduced the risk of death or tracheostomy (relative to placebo) by 24%, 34% and 31%, respectively (by 28%, 43% and 43%, respectively, after adjustment for known prognostic factors). This survival advantage (6-9 patients require treatment with riluzole to avoid 1 death/tracheostomy annually) compares favourably with that achieved therapeutically in breast cancer and coronary artery disease. Some 6000 ALS patients are currently receiving riluzole 50 mg twice daily within the Riluzole Early Access Program. In France, this programme is being implemented as an open-label multicentre trial to assess patients' functional status and quality of life. To date, 844 patients have been enrolled, and they will be followed up for 12 months on riluzole. Baseline demographic and clinical characteristics of this study population are presented here.

References

Oct 1, 1989·Muscle & Nerve·C K JableckiJ Leach
Aug 1, 1993·Journal of the Neurological Sciences·F NorrisH Norris
Mar 3, 1994·The New England Journal of Medicine·G BensimonV Meininger
Aug 3, 1996·Lancet·R J GuiloffJ Emami

❮ Previous
Next ❯

Citations

Nov 25, 2000·Journal of the Neurological Sciences·O Hurko, F S Walsh
Jan 3, 2001·The European Journal of Neuroscience·A Nógrádi, G Vrbová
Jun 18, 2002·Acta Neurologica Scandinavica·I Niebroj-DoboszH Kwieciński
Mar 16, 2012·The Cochrane Database of Systematic Reviews·Robert G MillerDan H Moore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.